PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life.

Santonati A, Palermo A, Maddaloni E, Bosco D, Spada A, Grimaldi F, Raggiunti B, Volpe R, Manfrini S, Vescini F

The Journal of clinical endocrinology and metabolism21 Jul 2015Cited by 45 (Europe PMC)

PMID26196949DOI10.1210/jc.2015-1855PepBankPUB-26196949

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with surgical hypoparathyroidism, serum calcium increased with PTH(1-34) from baseline to 15 days and then remained stable.
In plain wordsIn adults with surgical hypoparathyroidism, PTH(1-34) increased blood calcium compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum calcium
Study
n = 42
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
20 μg twice daily · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Serum calcium
7.6 mg/dL
baseline
Serum calcium
9.1 mg/dL
15 days of PTH(1-34)
Source sentences
Summary
The mean serum calcium levels significantly increased from baseline to 15 days (7.6 ± 0.6 vs 9.1 ± 0.9 mg/dL, P < .001) and remained stable until the end of the observational period, despite a significant reduction in calcium and vitamin D supplementation.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants included 42 subjects with surgical hypoparathyroidism (90% females, age range 34-77 y).InterventionThe intervention included a twice-daily PTH(1-34) 20 μg sc injection.
Report a problemFND-2619694901
02HumanNon-randomized trialEfficacy outcome
In adults with surgical hypoparathyroidism, calcium supplementation decreased during PTH(1-34) treatment compared with baseline.
In plain wordsIn adults with surgical hypoparathyroidism, calcium supplement needs decreased during PTH(1-34) treatment compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCalcium supplementation requirement
Study
n = 42
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
20 μg twice daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
despite a significant reduction in calcium and vitamin D supplementation
1 context sentence(design, population, supporting numbers)
Summary · context
Participants included 42 subjects with surgical hypoparathyroidism (90% females, age range 34-77 y).InterventionThe intervention included a twice-daily PTH(1-34) 20 μg sc injection.
Report a problemFND-2619694902
03HumanNon-randomized trialEfficacy outcome
In adults with surgical hypoparathyroidism, vitamin D supplementation decreased during PTH(1-34) treatment compared with baseline.
In plain wordsIn adults with surgical hypoparathyroidism, vitamin D supplement needs decreased during PTH(1-34) treatment compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVitamin D supplementation requirement
Study
n = 42
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
20 μg twice daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
despite a significant reduction in calcium and vitamin D supplementation
1 context sentence(design, population, supporting numbers)
Summary · context
Participants included 42 subjects with surgical hypoparathyroidism (90% females, age range 34-77 y).InterventionThe intervention included a twice-daily PTH(1-34) 20 μg sc injection.
Report a problemFND-2619694903
04HumanNon-randomized trialEfficacy outcome
In adults with surgical hypoparathyroidism, phosphate decreased from baseline through the sixth month of PTH(1-34) treatment.
In plain wordsIn adults with surgical hypoparathyroidism, phosphate decreased during PTH(1-34) treatment compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePhosphate
Study
n = 42
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
20 μg twice daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Phosphate levels gradually decreased from baseline to the sixth month (P = .005 for the trend), whereas the alkaline phosphatase increased (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants included 42 subjects with surgical hypoparathyroidism (90% females, age range 34-77 y).InterventionThe intervention included a twice-daily PTH(1-34) 20 μg sc injection.
Report a problemFND-2619694904
05HumanNon-randomized trialEfficacy outcome
In adults with surgical hypoparathyroidism, alkaline phosphatase increased during PTH(1-34) treatment compared with baseline.
In plain wordsIn adults with surgical hypoparathyroidism, alkaline phosphatase increased during PTH(1-34) treatment compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAlkaline phosphatase
Study
n = 42
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg twice daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Phosphate levels gradually decreased from baseline to the sixth month (P = .005 for the trend), whereas the alkaline phosphatase increased (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants included 42 subjects with surgical hypoparathyroidism (90% females, age range 34-77 y).InterventionThe intervention included a twice-daily PTH(1-34) 20 μg sc injection.
Report a problemFND-2619694905
06HumanNon-randomized trialEfficacy outcome
In adults with surgical hypoparathyroidism, all eight survey domain scores improved during PTH(1-34) treatment compared with baseline.
In plain wordsIn adults with surgical hypoparathyroidism, all eight quality-of-life scores improved during PTH(1-34) treatment compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseQuality of life across eight domains
Study
n = 42
Outcome group
Quality of life · Whole body
Studied dose
20 μg twice daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Data from the Rand 36-Item Short Form Health Survey showed a significant improvement in the mean scores of all eight domains (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants included 42 subjects with surgical hypoparathyroidism (90% females, age range 34-77 y).InterventionThe intervention included a twice-daily PTH(1-34) 20 μg sc injection.
Report a problemFND-2619694906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.